Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors

• Main Authors: Barbora Svobodova, Eva Mezeiova, Vendula Hepnarova, Martina Hrabinova, Lubica Muckova, Tereza Kobrlova, Daniel Jun, Ondrej Soukup, María Luisa Jimeno, José Marco-Contelles, Jan Korabecny
• Format: Article
• Language: English
• Published: MDPI AG 2019-08-01
• Series: Biomolecules
• Subjects: tacrine; bis(7)-tacrine; 6-chlorotacrine; 7-methoxytacrine; squaramides; Alzheimer’s disease; cholinesterases; in vitro; in silico
• Online Access: https://www.mdpi.com/2218-273X/9/8/379

Tacrine was the first drug to be approved for Alzheimer&#8217;s disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. The portfolio of currently approved drugs for AD includes acetylcholinesterase inhibitors (AChEIs) and <i>N</i>-methyl-<span style="font-variant: small-caps;">d</span>-aspartate (NMDA) receptor antagonist. Squaric acid is a versatile structural scaffold capable to be easily transformed into amide-bearing compounds that feature both hydrogen bond donor and acceptor groups with the possibility to create multiple interactions with complementary sites. Considering the relatively simple synthesis approach and other interesting properties (rigidity, aromatic character, H-bond formation) of squaramide motif, we combined this scaffold with different tacrine-based derivatives. In this study, we developed 21 novel dimers amalgamating squaric acid with either tacrine, 6-chlorotacrine or 7-methoxytacrine representing various AChEIs. All new derivatives were evaluated for their anti-cholinesterase activities, cytotoxicity using HepG2 cell line and screened to predict their ability to cross the blood-brain barrier. In this contribution, we also report in silico studies of the most potent AChE and BChE inhibitors in the active site of these enzymes.